Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
ORTHOWORLD estimates segment revenue and as-reported growth as follows.
1Q17
1Q16
$ Change
% Change
Spine
$11.7
$11.1
$0.6
5.1%
Orthobiologics
$10.4
$9.8
$0.5
5.5%
Total
$22.1
$21.0
$1.1
5.3%
Three priorities for 2017: revise strategic position/goals, optimize the sales channel and improve inventory utilization
Majority of YoY growth derived from increase in revenue from biologics: 3Demin 1Q17 revenue $1.6MM, +71% vs. 1Q16; OsteoVive is fastest-growing revenue category company’s biologic portfolio; OsteoSponge showing double-digit growth vs. 1Q16
Will address portfolio gaps via licensing agreements (in final stages for a few of them, presently)
Revenue from top 10 distributors grew +44% vs. 1Q16, generating 60% of commissioned revenue
Guidance update: withdrew previously-provided 2017 guidance (in a range from $96.0MM to $98.0MM) in light of ongoing review of its capital structure with Orbimed, its principle debt holder; update to come after review is complete
Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
ORTHOWORLD estimates segment revenue and as-reported growth as follows.
Q17 Q16 $ Change % Change
Spine $11.7 $11.1 $0.6 ...
Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
ORTHOWORLD estimates segment revenue and as-reported growth as follows.
1Q17
1Q16
$ Change
% Change
Spine
$11.7
$11.1
$0.6
5.1%
Orthobiologics
$10.4
$9.8
$0.5
5.5%
Total
$22.1
$21.0
$1.1
5.3%
Three priorities for 2017: revise strategic position/goals, optimize the sales channel and improve inventory utilization
Majority of YoY growth derived from increase in revenue from biologics: 3Demin 1Q17 revenue $1.6MM, +71% vs. 1Q16; OsteoVive is fastest-growing revenue category company’s biologic portfolio; OsteoSponge showing double-digit growth vs. 1Q16
Will address portfolio gaps via licensing agreements (in final stages for a few of them, presently)
Revenue from top 10 distributors grew +44% vs. 1Q16, generating 60% of commissioned revenue
Guidance update: withdrew previously-provided 2017 guidance (in a range from $96.0MM to $98.0MM) in light of ongoing review of its capital structure with Orbimed, its principle debt holder; update to come after review is complete
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
